Why Is This Rare Disease-Focused Soligenix Stock Trading Over 200% Today? - Soligenix (NASDAQ:SNGX)

The FDA has cleared Soligenix Inc's (NASDAQ: SNGX) Investigational New Drug (IND) application for a Phase 2a clinical trial for SGX945 (dusquetide) for aphthous 

Related Keywords

Turkey , ,Soligenix Inc ,New Drug ,